[
  {
    "ts": null,
    "headline": "Truist Securities Maintains Quest Diagnostics (DGX) Hold Recommendation",
    "summary": "Truist Securities Maintains Quest Diagnostics (DGX) Hold Recommendation",
    "url": "https://finnhub.io/api/news?id=c996128a4331a29878a600b0d7bd02d9c0281032920a592f69ab6789b59fd445",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761177257,
      "headline": "Truist Securities Maintains Quest Diagnostics (DGX) Hold Recommendation",
      "id": 137193357,
      "image": "",
      "related": "DGX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c996128a4331a29878a600b0d7bd02d9c0281032920a592f69ab6789b59fd445"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation",
    "summary": "Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=ea6385c5e0fe7567569a063f162cd40baeba59b0ace90d2ee9f49f4b0dcaf3f2",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761177256,
      "headline": "Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation",
      "id": 137193358,
      "image": "",
      "related": "DGX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ea6385c5e0fe7567569a063f162cd40baeba59b0ace90d2ee9f49f4b0dcaf3f2"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Incorporated (DGX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Quest Diagnostics Incorporated on Quality Value Investing’s Substack by David J. Waldron. In this article, we will summarize the bulls’ thesis on DGX. Quest Diagnostics Incorporated’s share was trading at $185.39 as of October 14th. DGX’s trailing and forward P/E were 21.67 and 17.12 respectively according to Yahoo Finance. Quest […]",
    "url": "https://finnhub.io/api/news?id=a97f5feda52d6771d55b1ad58860407e2ae350912ca7fbad51628e9cc2446b88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761169012,
      "headline": "Quest Diagnostics Incorporated (DGX): A Bull Case Theory",
      "id": 137218126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Quest Diagnostics Incorporated on Quality Value Investing’s Substack by David J. Waldron. In this article, we will summarize the bulls’ thesis on DGX. Quest Diagnostics Incorporated’s share was trading at $185.39 as of October 14th. DGX’s trailing and forward P/E were 21.67 and 17.12 respectively according to Yahoo Finance. Quest […]",
      "url": "https://finnhub.io/api/news?id=a97f5feda52d6771d55b1ad58860407e2ae350912ca7fbad51628e9cc2446b88"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Margins a Blip as Fundamentals Stay Strong, Morgan Stanley Says",
    "summary": "Quest Diagnostics' (DGX) fundamentals remain strong despite a temporary margin \"blip\" that weighed o",
    "url": "https://finnhub.io/api/news?id=ce797682feae30b37dd06c1664cabe1a9bed6a5069c4a6738c1547b627df0c3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761148775,
      "headline": "Quest Diagnostics Margins a Blip as Fundamentals Stay Strong, Morgan Stanley Says",
      "id": 137189043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics' (DGX) fundamentals remain strong despite a temporary margin \"blip\" that weighed o",
      "url": "https://finnhub.io/api/news?id=ce797682feae30b37dd06c1664cabe1a9bed6a5069c4a6738c1547b627df0c3a"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead",
    "summary": "Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for DGX stockâs outlook and potential.",
    "url": "https://finnhub.io/api/news?id=6a2cf6f5d90356c69c1900308b3b5d9cdc29d7258b5a562a06fcb82165383fb6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761145858,
      "headline": "Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead",
      "id": 137190623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/120526728/image_120526728.jpg?io=getty-c-w1536",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for DGX stockâs outlook and potential.",
      "url": "https://finnhub.io/api/news?id=6a2cf6f5d90356c69c1900308b3b5d9cdc29d7258b5a562a06fcb82165383fb6"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=4cc71ac2e23d6c14ce75a84f4f9e560ace63e25a7c8f6bc74a1e99f10baa2333",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761140703,
      "headline": "Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock",
      "id": 137189044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=4cc71ac2e23d6c14ce75a84f4f9e560ace63e25a7c8f6bc74a1e99f10baa2333"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Partners Maintains Quest Diagnostics (DGX) Outperform Recommendation",
    "summary": "Leerink Partners Maintains Quest Diagnostics (DGX) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=0f8aef6c17d64da16b2e7c7d5f3216097193731ad455248c6cffc15f1d323acd",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761134756,
      "headline": "Leerink Partners Maintains Quest Diagnostics (DGX) Outperform Recommendation",
      "id": 137186492,
      "image": "",
      "related": "DGX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0f8aef6c17d64da16b2e7c7d5f3216097193731ad455248c6cffc15f1d323acd"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics (DGX): 15.4% Earnings Growth Challenges Slower-Growth Narrative",
    "summary": "Quest Diagnostics (DGX) delivered a 15.4% earnings growth over the past year, beating its five-year average where earnings had declined by 18.5% per year. Analysts are calling for continued but slower EPS growth at 8.9% per year and revenue increases of 3.4% annually. Both rates trail the broader US market’s growth rates. Margins have edged higher, with the company posting a net profit margin of 8.9%, a slight uptick from last year’s 8.8%, reflecting gradual improvements in near-term...",
    "url": "https://finnhub.io/api/news?id=88a53b6e2fee74324743cd207bfcaf0c3d0e0dab84605f7eb90cc44f65710df8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761131638,
      "headline": "Quest Diagnostics (DGX): 15.4% Earnings Growth Challenges Slower-Growth Narrative",
      "id": 137189045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (DGX) delivered a 15.4% earnings growth over the past year, beating its five-year average where earnings had declined by 18.5% per year. Analysts are calling for continued but slower EPS growth at 8.9% per year and revenue increases of 3.4% annually. Both rates trail the broader US market’s growth rates. Margins have edged higher, with the company posting a net profit margin of 8.9%, a slight uptick from last year’s 8.8%, reflecting gradual improvements in near-term...",
      "url": "https://finnhub.io/api/news?id=88a53b6e2fee74324743cd207bfcaf0c3d0e0dab84605f7eb90cc44f65710df8"
    }
  }
]